Drug Trial Radar · NCT02943655
Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause
Last checked: Nov 20, 2026Latest source record: Jun 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Nov 1, 2017
Primary completion
Oct 10, 2020
Study completion Feb 10, 2021
Sponsor
- Lead sponsor
- Assiut UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 25 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Abnormal uterine bleeding encompasses abnormalities in the regularity, duration of flow, frequency, and/or blood flow volume relative to normal menstruation. Of these menstrual abnormalities, heavy menstrual bleeding (HMB), defined objectively as a blood loss of 80 ml or more per menstrual cycle , which is unrelated to pregnancy or known pelvic or systemic disease.
Conditions
- Improve Quality of Life
- Heavy Menstrual Bleeding
Interventions
combined contraceptive pills (microcept)Drug
oral combined contraceptive once daily
medroxyprogesterone acetate (progest)Drug
oral 5 mg medroxyprogesterone acetate daily
mefenamic acid (ponstan forte)Drug
oral 500 mg mefenamic acid three times per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- the amount of menstrual blood lossTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ahmed Abbas
Assiut, Cairo Governorate, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.